GLP-1s (or GLP-1RAs/receptor-agonists), including semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), and others, have sparked a lot of interest among patients and practitioners treating lipedema. Could this be helpful for lipedema? Who is most likely to benefit?
These medications work by mimicking the GLP-1 hormone which helps with blood sugar regulation, reducing appetite, and slowing digestion. Though these medications are not currently approved to treat lipedema, emerging mechanistic evidence suggests they may have disease-modifying potential through effects on inflammation, fibrosis, and adipose tissue remodeling.[1] Direct clinical evidence in lipedema patients is currently lacking.
GLP-1 receptor agonists demonstrate several adipose tissue effects that could theoretically benefit lipedema, however, are not entirely specific to the pathophysiology of lipedema:
- Reduced visceral and subcutaneous fat and fat redistribution: GLP-1RAs significantly decrease both visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT) in patients with diabetes and obesity. [2-3] Liraglutide preferentially reduces visceral fat while relatively preserving subcutaneous fat and promotes browning of subcutaneous adipose tissue. [4]
These findings may not translate to lipedema, where the pathophysiology involves disproportionate subcutaneous fat accumulation in the lower fat extremities. Visceral fat is not typically involved in lipedema.
- Anti-inflammatory effects: GLP-1RAs decrease proinflammatory adipokines and reduce expression of inflammatory genes in adipose tissue. [5-6]
It is currently unclear whether this will specifically benefit lipedema patients where inflammation is driven by different mechanisms than obesity and has distinct characteristics.
- Metabolic improvements: These agents down-regulate lipogenic genes while increasing lipolytic markers and adiponectin expression. [6]
While these changes may be beneficial to many patients with lipedema, much of the metabolic benefit of GLP-1s do not directly translate to lipedema. Patients with lipedema tend to have lower rates of metabolic syndrome, hyperlipidemia, and hyperglycemia.
- Anti-fibrotic effects: Tirzepatide, as a dual GLP-1/GIP receptor agonist, demonstrates additional effects on macrophage polarization, extracellular matrix turnover, and antifibrotic pathways that may be particularly relevant to lipedema’s fibro-inflammatory pathology.
Who would benefit the most from GLP-1s? Theoretical mechanistic considerations:
Given the known effects of GLP-1RAs on adipose tissue biology, certain lipedema patient subgroups might theoretically derive benefit:
Patients with concurrent obesity or metabolic comorbidities
Due to the impacts on blood sugar regulation and obesity, some patients with lipedema may experience greater benefit if they have additional issues here including diabetes, prediabetes, metabolic syndrome, or insulin resistance. An important consideration is that many people have normal blood sugar levels but still have insulin resistance which may be affecting metabolic health and contributing to weight loss resistance.
Patients with inflammatory features
This population might theoretically benefit from the anti-inflammatory effects of GLP-1RAs, which decrease proinflammatory adipokines and reduce inflammatory gene expression in adipose tissue.[9] However, lipedema exhibits a distinct M2 macrophage-predominant anti-inflammatory profile rather than the M1 pro-inflammatory response seen in obesity, making it unclear whether GLP-1RA anti-inflammatory effects would translate to lipedema.[10]
Postmenopausal patients represent another theoretical target given emerging evidence of GLP-1 and estrogen pathway interactions in regulating lipid metabolism, and the recognition of menopause as a critical turning point in lipedema progression driven by estrogen receptor imbalance.[10-11]
GLP1-RAs can be an excellent tool in the right populations and should be considered in patients with lipedema on an individual basis.
Sources
1. Tirzepatide as a Potential Disease-Modifying Therapy in Lipedema: A Narrative Review on Bridging Metabolism, Inflammation, and Fibrosis. International Journal of Molecular Sciences. 2025. Viana DPDC, Invitti AL, Schor E.
Journal of Diabetes and Its Complications. 2024. Xie W, Hong Z, Li B, et al.
3. Short-Term Effects of Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists on Fat Distribution in Patients With Type 2 Diabetes Mellitus: An Ultrasonography Study. Acta Diabetologica. 2015. Morano S, Romagnoli E, Filardi T, et al.
4. The Key Role of a Glucagon-Like Peptide-1 Receptor Agonist in Body Fat Redistribution. The Journal of Endocrinology. 2019. Zhao L, Zhu C, Lu M, et al.
5. Impact of Selected Glucagon-Like Peptide-1 Receptor Agonists on Serum Lipids, Adipose Tissue, and Muscle Metabolism-a Narrative Review. International Journal of Molecular Sciences. 2024. Szekeres Z, Nagy A, Jahner K, Szabados E.
6. Effects of Glucagon-Like Peptide-1 on the Differentiation and Metabolism of Human Adipocytes. British Journal of Pharmacology. 2016. El Bekay R, Coín-Aragüez L, Fernández-García D, et al.
7. FDA Orange Book. FDA Orange Book. 2026.
8. Medications for Obesity: A Review. The Journal of the American Medical Association. 2024. Gudzune KA, Kushner RF.
9. Impact of Selected Glucagon-Like Peptide-1 Receptor Agonists on Serum Lipids, Adipose Tissue, and Muscle Metabolism-a Narrative Review. International Journal of Molecular Sciences. 2024. Szekeres Z, Nagy A, Jahner K, Szabados E.
10. Lipedema and Adipose Tissue: Current Understanding, Controversies, and Future Directions. Frontiers in Cell and Developmental Biology. 2025. Rabiee A.
11. Interactions Between Glucagon Like Peptide 1 (GLP-1) and Estrogens Regulates Lipid Metabolism. Biochemical Pharmacology. 2024. Model JFA, Normann RS, Vogt ÉL, et al.
